Tetraphase Pharmaceuticals Inc (TTPH) 9.00 $TTPH
Tetraphase Pharmaceuticals Reports First-Quarter 2014 Financial Results
Business Wire - Mon May 12, 7:29AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant (MDR) bacteria, today reported financial results for the quarter ended March 31, 2014. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat MDR infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Tetraphase to Present Data on Advancing Product Pipeline at 24th ECCMID
Business Wire - Fri May 09, 7:02PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the upcoming presentation of six scientific posters at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place May 10-13, 2014 in Barcelona, Spain.
Is Tetraphase (TTPH) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:28AM CDT
Is Tetraphase (TTPH) Ready to Breakout?
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day
Tetraphase Pharmaceuticals, Inc. [TTPH] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Apr 07, 9:00AM CDT
What:
Fast-Track Status for Tetraphase Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:05PM CDT
Shares of Tetraphase Pharma were up 2.5% after the company received Fast Track designation from FDA for its lead antibiotic candidate, eravacycline.
FDA Awards Fast Track Status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline
Business Wire - Wed Apr 02, 7:33AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline. Tetraphase is investigating the safety and efficacy of eravacycline in its ongoing Phase 3 global clinical program; the IGNITE 1 study is evaluating the IV formulation of eravacycline for the treatment of complicated intra-abdominal infections (cIAI); IGNITE 2 is evaluating eravacycline IV-to-oral step-down therapy for the treatment of complicated urinary tract infections (cUTI).
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Tetraphase's Eravacycline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 10:30AM CDT
Tetraphase is working hard to develop its pipeline.
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Fri Mar 21, 8:03AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline
Business Wire - Thu Mar 20, 7:33AM CDT
--Enrollment underway in IGNITE 2 Phase 3 clinical trial of IV/oral eravacycline in complicated urinary tract infections
Tetraphase Pharmaceuticals Adds Nancy J. Wysenski to Board of Directors
Business Wire - Thu Mar 13, 7:35AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced the addition of Nancy J. Wysenski to the company's Board of Directors. Ms. Wysenski has more than 35 years' experience in the life science industry, the majority of which have been spent in commercial leadership roles.
What Falling Estimates & Price Mean for Tetraphase Pharmaceuticals (TTPH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:15AM CDT
One such stock that you may want to consider dropping is Tetraphase Pharmaceuticals which witnessed negative earnings estimate revisions in current quarter and current year.
Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.
Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tetraphase Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 8:03AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11th at 3:00 p.m. Eastern Time. The conference will take place February 10 - 11 at the Waldorf Astoria in New York City.
Tetraphase Pharmaceuticals Reports First-Quarter 2014 Financial Results
Business Wire - Mon May 12, 7:29AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant (MDR) bacteria, today reported financial results for the quarter ended March 31, 2014. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat MDR infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Tetraphase to Present Data on Advancing Product Pipeline at 24th ECCMID
Business Wire - Fri May 09, 7:02PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the upcoming presentation of six scientific posters at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place May 10-13, 2014 in Barcelona, Spain.
Is Tetraphase (TTPH) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:28AM CDT
Is Tetraphase (TTPH) Ready to Breakout?
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day
Tetraphase Pharmaceuticals, Inc. [TTPH] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Apr 07, 9:00AM CDT
What:
Fast-Track Status for Tetraphase Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:05PM CDT
Shares of Tetraphase Pharma were up 2.5% after the company received Fast Track designation from FDA for its lead antibiotic candidate, eravacycline.
FDA Awards Fast Track Status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline
Business Wire - Wed Apr 02, 7:33AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline. Tetraphase is investigating the safety and efficacy of eravacycline in its ongoing Phase 3 global clinical program; the IGNITE 1 study is evaluating the IV formulation of eravacycline for the treatment of complicated intra-abdominal infections (cIAI); IGNITE 2 is evaluating eravacycline IV-to-oral step-down therapy for the treatment of complicated urinary tract infections (cUTI).
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Tetraphase's Eravacycline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 10:30AM CDT
Tetraphase is working hard to develop its pipeline.
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Fri Mar 21, 8:03AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline
Business Wire - Thu Mar 20, 7:33AM CDT
--Enrollment underway in IGNITE 2 Phase 3 clinical trial of IV/oral eravacycline in complicated urinary tract infections
Tetraphase Pharmaceuticals Adds Nancy J. Wysenski to Board of Directors
Business Wire - Thu Mar 13, 7:35AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced the addition of Nancy J. Wysenski to the company's Board of Directors. Ms. Wysenski has more than 35 years' experience in the life science industry, the majority of which have been spent in commercial leadership roles.
What Falling Estimates & Price Mean for Tetraphase Pharmaceuticals (TTPH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:15AM CDT
One such stock that you may want to consider dropping is Tetraphase Pharmaceuticals which witnessed negative earnings estimate revisions in current quarter and current year.
Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.
Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tetraphase Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 8:03AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11th at 3:00 p.m. Eastern Time. The conference will take place February 10 - 11 at the Waldorf Astoria in New York City.
